HRP20221294T1 - Neuroaktivni steroidi, njihovi pripravci i uporabe - Google Patents
Neuroaktivni steroidi, njihovi pripravci i uporabe Download PDFInfo
- Publication number
- HRP20221294T1 HRP20221294T1 HRP20221294TT HRP20221294T HRP20221294T1 HR P20221294 T1 HRP20221294 T1 HR P20221294T1 HR P20221294T T HRP20221294T T HR P20221294TT HR P20221294 T HRP20221294 T HR P20221294T HR P20221294 T1 HRP20221294 T1 HR P20221294T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical preparation
- administered
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 201000006517 essential tremor Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Spoj formule:
[image]
za uporabu u postupku za liječenje esencijalnog tremora kod subjekta kojem je to potrebno, koji obuhvaća primjenu spoja kod subjekta.
2. Spoj za uporabu kao u patentnom zahtjevu 1, naznačen time što se spoj primjenjuje oralno, subkutano, intravenski ili intramuskularno.
3. Spoj za uporabu kao u patentnom zahtjevu 1, naznačen time što se spoj primjenjuje kronično.
4. Spoj za uporabu kao u patentnom zahtjevu 2, naznačen time što se spoj primjenjuje oralno.
5. Spoj za uporabu kao u patentnom zahtjevu 2, naznačen time što se spoj primjenjuje intravenski.
6. Farmaceutski prihvatljiva sol spoja formule:
[image]
za uporabu u postupku za liječenje esencijalnog tremora kod subjekta kojem je to potrebno, koji obuhvaća primjenu farmaceutski prihvatljive soli spoja kod subjekta.
7. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 6, naznačena time što se farmaceutski prihvatljiva sol primjenjuje oralno, subkutano, intravenski ili intramuskularno.
8. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 6, naznačena time što se farmaceutski prihvatljiva sol primjenjuje kronično.
9. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 7, naznačena time što se farmaceutski prihvatljiva sol primjenjuje oralno.
10. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 7, naznačena time što se farmaceutski prihvatljiva sol primjenjuje intravenski.
11. Farmaceutski pripravak koji sadrži spoj formule:
[image]
i farmaceutski prihvatljiv ekscipijens za uporabu u postupku za liječenje esencijalnog tremora kod subjekta kojem je to potrebno, koji obuhvaća primjenu pripravka kod subjekta.
12. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 11, naznačen time što se farmaceutski pripravak primjenjuje oralno, subkutano, intravenski ili intramuskularno.
13. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 11, naznačen time što se farmaceutski pripravak primjenjuje kronično.
14. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 12, naznačen time što se farmaceutski pripravak primjenjuje oralno.
15. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 12, naznačen time što se farmaceutski pripravak primjenjuje intravenski.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014078820 | 2014-05-29 | ||
| EP20171670.1A EP3705488B1 (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221294T1 true HRP20221294T1 (hr) | 2023-03-03 |
Family
ID=54698130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201126TT HRP20201126T1 (hr) | 2014-05-29 | 2015-05-29 | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| HRP20221294TT HRP20221294T1 (hr) | 2014-05-29 | 2015-05-29 | Neuroaktivni steroidi, njihovi pripravci i uporabe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201126TT HRP20201126T1 (hr) | 2014-05-29 | 2015-05-29 | Neuroaktivni steroidi, njihovi pripravci i uporabe |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20180179247A1 (hr) |
| EP (3) | EP4144746A1 (hr) |
| JP (4) | JP6652934B2 (hr) |
| KR (3) | KR20240066304A (hr) |
| CN (3) | CN106661078A (hr) |
| AR (2) | AR100691A1 (hr) |
| AU (4) | AU2015266447A1 (hr) |
| CA (1) | CA2949720A1 (hr) |
| CY (1) | CY1124109T1 (hr) |
| DK (2) | DK3149018T3 (hr) |
| ES (2) | ES2805598T3 (hr) |
| HR (2) | HRP20201126T1 (hr) |
| HU (2) | HUE059829T2 (hr) |
| IL (3) | IL248948B (hr) |
| JO (1) | JO3691B1 (hr) |
| LT (2) | LT3705488T (hr) |
| MX (5) | MX394493B (hr) |
| PH (2) | PH12021550762A1 (hr) |
| PL (2) | PL3705488T3 (hr) |
| PT (2) | PT3149018T (hr) |
| RS (2) | RS60529B1 (hr) |
| RU (2) | RU2699359C2 (hr) |
| SG (2) | SG10201803812TA (hr) |
| SI (2) | SI3705488T1 (hr) |
| SM (2) | SMT202200416T1 (hr) |
| TW (3) | TWI839649B (hr) |
| WO (1) | WO2015180679A1 (hr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1959966B1 (en) | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Ganaxolone formulations and methods for the making and use thereof |
| JP2014528485A (ja) | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| JP6355633B2 (ja) | 2012-08-21 | 2018-07-11 | セージ セラピューティクス， インコーポレイテッド | てんかんまたはてんかん重積状態の処置方法 |
| CN105246909B (zh) | 2013-04-17 | 2020-10-13 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| US9512165B2 (en) | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| DK3021852T3 (da) | 2013-07-19 | 2021-03-15 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
| PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| AU2015266447A1 (en) * | 2014-05-29 | 2016-12-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN118344424A (zh) | 2014-10-16 | 2024-07-16 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| SI3206493T1 (sl) | 2014-10-16 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| PT3250210T (pt) | 2015-01-26 | 2021-03-26 | Sage Therapeutics Inc | Composições e métodos para o tratamento de distúrbios do snc |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| MX2018004376A (es) | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
| SG11201807785VA (en) * | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| EP3481845B1 (en) * | 2016-07-11 | 2023-09-13 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AU2018388408B2 (en) * | 2017-12-22 | 2023-12-21 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| EP3750908A4 (en) | 2018-02-11 | 2022-07-27 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| EP3911331A4 (en) * | 2019-01-14 | 2023-01-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF |
| PH12021553005A1 (en) | 2019-05-31 | 2023-08-14 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF STATUS EPILEPTICUS |
| EP4011897A4 (en) | 2019-08-07 | 2024-02-21 | Shanghai Hansoh Biomedical Co., Ltd. | SALT AND CRYSTAL FORM OF A STEROID DERIVATIVE REGULATOR |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| AU2022214187A1 (en) | 2021-01-28 | 2023-07-13 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| CN117693516A (zh) | 2021-07-28 | 2024-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇的晶型 |
| WO2023164387A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| WO2024189061A1 (en) | 2023-03-14 | 2024-09-19 | Curia Spain, S.A.U. | Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids |
| WO2024230797A1 (zh) * | 2023-05-11 | 2024-11-14 | 上海枢境生物科技有限公司 | 甾体类化合物、制备方法及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634717A1 (de) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | Verfahren zur herstellung von 5-methyltetrazol |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| FR2679263B1 (fr) * | 1991-07-15 | 1994-01-14 | Staubli Ets | Perfectionnements aux ratieres a double leve du type hattersley pour machines a tisser. |
| ATE375993T1 (de) * | 1994-02-14 | 2007-11-15 | Euro Celtique Sa | Androstane und pregane zur allosterischen modulation des gaba rezeptors |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| AU780989B2 (en) * | 1999-04-29 | 2005-04-28 | Euro-Celtique S.A. | 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity |
| EP1558132B1 (en) * | 2002-10-15 | 2011-12-21 | Medtronic, Inc. | Medical device system for scoring of sensed neurological events |
| US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
| JP2014528485A (ja) * | 2011-10-14 | 2014-10-27 | セージ セラピューティクス， インコーポレイテッド | ３，３−二置換１９−ノルプレグナン化合物およびその使用 |
| AU2015266447A1 (en) * | 2014-05-29 | 2016-12-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SI3206493T1 (sl) * | 2014-10-16 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
-
2015
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Pending
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 PH PH1/2021/550762A patent/PH12021550762A1/en unknown
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 MX MX2020000789A patent/MX394493B/es unknown
- 2015-05-29 KR KR1020237003114A patent/KR102664412B1/ko active Active
- 2015-05-29 MX MX2016015532A patent/MX382131B/es unknown
- 2015-05-29 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2015-05-29 SM SM20220416T patent/SMT202200416T1/it unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 TW TW110139343A patent/TWI839649B/zh active
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 SM SM20200406T patent/SMT202000406T1/it unknown
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 TW TW112143683A patent/TW202426001A/zh unknown
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active Active
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en not_active Abandoned
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| HRP20210241T1 (hr) | Derivat policikličkog piridona protiv gripe i njegov predlijek | |
| HRP20171512T1 (hr) | Derivati betulina | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| JP2019516735A5 (hr) | ||
| HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| ME02841B (me) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| EA201592279A1 (ru) | Фармацевтическая композиция, ее получение и применение | |
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| HRP20211107T1 (hr) | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease |